Cellular Oncology

Cellular Oncology

细胞肿瘤学

  • 2区 中科院分区
  • Q1 JCR分区

期刊简介

《Cellular Oncology》是由Springer Netherlands出版社于2011年创办的英文国际期刊(ISSN: 2211-3428,E-ISSN: 2211-3436),该期刊长期致力于细胞生物学领域的创新研究,主要研究方向为ONCOLOGY-CELL BIOLOGY。作为SCIE收录期刊(JCR分区 Q1,中科院 2区),本刊采用OA未开放获取模式(OA占比0.1373...%),以发表细胞生物学领域等方向的原创性研究为核心(研究类文章占比80.15%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在136篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Cellular Oncology审稿周期约为 约12月 。该刊近年未被列入国际预警名单,年发文量约136篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 136 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
2区
CELL BIOLOGY 细胞生物学 PATHOLOGY 病理学 ONCOLOGY 肿瘤学
2区 2区 3区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
2区
PATHOLOGY 病理学 CELL BIOLOGY 细胞生物学 ONCOLOGY 肿瘤学
1区 2区 2区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:CELL BIOLOGY SCIE Q2 67 / 205

67.6%

学科:ONCOLOGY SCIE Q1 68 / 322

79%

学科:PATHOLOGY SCIE Q1 11 / 88

88.1%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:CELL BIOLOGY SCIE Q1 44 / 205

78.78%

学科:ONCOLOGY SCIE Q1 63 / 322

80.59%

学科:PATHOLOGY SCIE Q1 16 / 88

82.39%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:10.3 SJR:1.489 SNIP:1.031
学科类别 分区 排名 百分位
大类:Medicine 小类:Oncology Q1 56 / 404

86%

大类:Medicine 小类:Molecular Medicine Q1 32 / 178

82%

大类:Medicine 小类:Cancer Research Q1 48 / 230

79%

期刊发文

  • Comprehensive analysis of clinical prognostic features and tumor microenvironment landscape of CD11b(+)CD64(+) patients with acute myeloid leukemia

    Author: Wang, Qian; Zhang, Nan; Liu, Li; Ma, Linlu; Tan, Yuxin; Liu, Xiaoyan; Wu, Jinxian; Chen, Guopeng; Li, Xinqi; Liang, Yuxing; Zhou, Fuling

    Journal: CELLULAR ONCOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s13402-023-00808-7

  • In vivo study revealed pro-tumorigenic effect of CMTM3 in hepatocellular carcinoma involving the regulation of peroxisome proliferator-activated receptor gamma (PPAR gamma)

    Author: Wang, Jiahui; Chu, Hongjin; Wang, Zhixin; Wang, Xuebo; Liu, Xuexia; Song, Zhan; Liu, Fujun

    Journal: CELLULAR ONCOLOGY. 2023; Vol. 46, Issue 1, pp. 49-64. DOI: 10.1007/s13402-022-00733-1

  • Research advances and treatment perspectives of pancreatic adenosquamous carcinoma

    Author: Zhang, Wen; Zhang, Jing; Liang, Xijun; Ding, Jin

    Journal: CELLULAR ONCOLOGY. 2023; Vol. 46, Issue 1, pp. 1-15. DOI: 10.1007/s13402-022-00732-2

  • FUT8 is regulated by miR-122-5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling

    Author: Chen, Fanghua; Li, Yin; Aye, Ling; Wu, Yingcheng; Dong, Liangqing; Yang, Zijian; Gao, Qiang; Zhang, Shu

    Journal: CELLULAR ONCOLOGY. 2023; Vol. 46, Issue 1, pp. 79-91. DOI: 10.1007/s13402-022-00736-y

  • PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity

    Author: Wang, Shuang; Liu, Ximeng; Zhou, Ting; Li, Jinling; Lin, Ying; Zhou, Anni; Huang, Jiamin; Zhao, Jingjing; Cai, Junchao; Cai, Xiuyu; Huang, Yongbo; Li, Xu

    Journal: CELLULAR ONCOLOGY. 2023; Vol. 46, Issue 1, pp. 195-209. DOI: 10.1007/s13402-022-00744-y

  • Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment

    Author: Zhu, Yu-Heng; Zheng, Jia-Hao; Jia, Qin-Yuan; Duan, Zong-Hao; Yao, Hong-Fei; Yang, Jian; Sun, Yong-Wei; Jiang, Shu-Heng; Liu, De-Jun; Huo, Yan-Miao

    Journal: CELLULAR ONCOLOGY. 2023; Vol. 46, Issue 1, pp. 17-48. DOI: 10.1007/s13402-022-00741-1

  • TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4(+)Foxp3(+) regulatory T cells

    Author: He, Tianzhen; Chen, Yibo; Yang, De; Islam, Md Sahidul; Chou, Chon-Kit; Liu, Jiarui; Faustman, Denise L.; Oppenheim, Joost J.; Chen, Xin

    Journal: CELLULAR ONCOLOGY. 2023; Vol. 46, Issue 1, pp. 167-177. DOI: 10.1007/s13402-022-00742-0

  • IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-kappa B signaling to promote colorectal cancer progression

    Author: He, Xiaoli; Wu, Nan; Li, Renlong; Zhang, Haohao; Zhao, Yu; Nie, Yongzhan; Wu, Jing

    Journal: CELLULAR ONCOLOGY. 2023; Vol. 46, Issue 1, pp. 145-164. DOI: 10.1007/s13402-022-00740-2